Eglin Pharmaceuticals' oral drug EG-009 for the treatment of neo-coronavirus pneumonia has been officially approved by the FDA for Phase I clinical trials.

EG-009 is one of Eglin Pharmaceuticals' nine research and development pipelines for treating cytokine storms caused by neocyto pneumonia.
cytokine storm is one of the leading causes of death in patients with neocytocytopathic pneumonia, and the oral preparation EG-009 is mainly used to prevent and treat cytokine storms caused by neocytovirus (cytonkine release sydrome).
EG-009 research and development will bring new hope to reduce the mortality rate of patients with neo-crown pneumonia at a time when the global epidemic of new coronary pneumonia continues.
Eglin began research and development of his new coronary therapy drug immediately after the outbreak of neo-crown pneumonia.
in preparation for clinical trials, but also for its new coronary therapy series of drugs basic research and patent filing has done a lot of layout.
, CEO of Eglin Pharmaceuticals, said, "Focusing on clinical needs and focusing on drug value is what we've always believed in."
Eglin as a fast-growing innovative pharmaceutical company, the continuous adjustment and continuous improvement of research and development pipeline is a regular work.
Eglin's research and development team will begin clinical trials of the project as soon as EG-009's IND is approved, in an effort to bring new treatment hopes to patients with new coronavirus infections at an early stage.
" . . . Coronavirus Treatment Speed Program About Eglin Pharmaceuticals Shenzhen Eglin Pharmaceutical Co., Ltd. ("Eglin") is a rapidly developing international biopharmaceutical company in the clinical stage, dedicated to the discovery and development of innovative drugs, as well as clinical research and development and commercialization worldwide.
's mission is to "focus on clinical needs and reach patients around the world", focusing on the development of innovative drugs in the areas of autoimmune, tumor immunity, and chronic diseases.
Eglin Pharmaceuticals adheres to a global and differentiated development strategy and actively develops new adaptations to existing drugs while exploring new targets.
, Drug Repurposing not only reduces research costs and accelerates research and development, but also increases the probability of success and the value of the drug.
Drug Repurposing is becoming a trend in the development of new drugs today, when the research and development cycle of new drugs is long and costly.
Eglin's corporate values of "closely focusing on clinical needs and accelerating innovative clinical development" and "abandoning the concept of corporate development that follows homogenization hotspots and focus on differentiated research and development" will continue to lead the future trend of the pharmaceutical industry with a "global perspective and a focus on pharmaceutical value".
Eglin upholds an open mind, vigorously promote independent research and development, but also actively promote strategic cooperation, in the world to seek cooperation opportunities, the introduction of high-quality products and first-class technology, in order to meet the urgent clinical needs of patients as soon as possible, to achieve enterprise value.
.